ReSync Bio is building the next generation of drug discovery tools for preclinical teams. While organizations are excited to add new AI tools to their workflows, the challenge of integrating models, storing data, and permissions access make it exceedingly difficult to adopt new technologies. Led by CEO Mihir Trivedi, ReSync is building a platform to centralize their communication, data, and computational tools in one location – enabling the development of next-generation therapies by helping drug discovery teams access the most cutting-edge tools for their workflows.
Company Background
- ReSync was founded based on hundreds of conversations with companies at the forefront of AI-enabled drug discovery, and their learnings from building infrastructure for closed-loop, automated operations.
- We learned that while all organizations were motivated to add AI tools to their workflows, integrating models, storing data, and permissioning access were creating months to years of new work for teams.
- Our team wants to make AI-enabled innovation accessible to every company, regardless of their starting point.
Solution Summary
- We’ve built a platform for small molecule discovery teams to centralize their communication, data, and computational tools.
- Our platform enables teams big and small to run design-make-test-analyze (DMTA) cycles efficiently by running large-scale virtual screens, tracking experimental workflows, and visualizing progress – all without scaling a computational team.
- ReSync curates top open source models and partners to make running AI tools within your DMTA cycle simple, removing the need to write any code or hire an engineering team.
- Our unified dashboards allow users to see data-rich visualizations of docking, tabular data, chemical structures, and more directly in their browser – no downloads required.
Case Study
- For a mid-size biotech company, ReSync helped a VP of Medicinal Chemistry gain visibility into chemists’ designs across her organization.
- Instead of emailed ChemDraw files, all virtual structures are registered and described on the ReSync platform.
- The customer is now able to run Docking simulations themselves and view results instantly, instead of making emailed requests to a computational CRO, then waiting days for the results to be sent back.
- During an evaluation, the biotech company found ReSync saved almost a full day a week in time spent searching for data or tracking requests for computational and experimental work.
Partnership Opportunities
- Biotechs, Pharma, Academics, and CROs can all be users of the @ReSync platform. We’re powerful for multi-team collaborations, including Joint Ventures, Consortiums, and multi-site organizations.
- Building predictive or generative models for small molecule drug discovery? Reach out to us at partnerships@resync.bio for more information on how our distribution network can help grow usage of your models.
About Merck Digital Sciences Studio:
The Merck Digital Sciences Studio (MDS Studio or MDSS) is a collaboration between Merck, the Merck Global Health Innovation Fund, Northpond Ventures, McKesson Ventures, Microsoft for Startups, and the New Jersey Innovation Institute, a New Jersey Institute of Technology (NJIT) subsidiary. The 10-month startup accelerator program empowers members and enables the generation of innovative digital technologies for drug discovery and development through hands-on mentorship, connection opportunities with industry-leading partners, and training in an active entrepreneurial setting. Through the accelerator program, these startups will have access to workshops, coaching, office space, and Microsoft for Startups resources, including up to $150,000 Azure Cloud computing credits.